Home › Atherosclerosis › Tennessee
Atherosclerosis clinical trials in Tennessee
9 studies for Atherosclerosis are looking for participants at sites in Tennessee.
Cities in Tennessee
Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07594392Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- WR-Clinsearch, LLC, Chattanooga
- Erlanger Health System, Chattanooga
- The Jackson Clinic, Jackson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- and 1 more
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Southeast Renal Research Institute, Chattanooga
- Dialysis Clinic Inc - University Nephology, Knoxville
- Knoxville Kidney Center PLLC, Knoxville
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Vanderbilt University School of Medicine (VUSM) - Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC), Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07448038A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Chattanooga
- Research Site, Chattanooga
- Research Site, Greeneville
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Novartis Investigative Site, Tullahoma
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Aug 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Apex Cardiology Research Associates of Jackson, Jackson
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06875973Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Memphis VA Medical Center, Memphis, TN, Memphis
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT02915198From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.